PEDEvidence
Latest studiesAll research questions
RESEARCH BY QUESTION

What has been studied for preserving muscle during weight loss?

Separate weight loss, lean mass and muscle function.

The selected human studies show different body-composition patterns. They do not establish a winning GLP combination for preserving functional muscle.

SURMOUNT-1 body-composition substudy Heymsfield et al., bimagrumab phase 2 trial Oral ghrelin mimetic in healthy older adults
Compare measured outcomesWatch relevant trials
Human

How much of the weight lost was lean mass?

10.9% lean-mass reduction

SURMOUNT-1 DXA substudy: 124 tirzepatide and 36 placebo participants; 72 weeks.

Demonstrated findings

At 72 weeks, fat mass fell 33.9% and lean mass 10.9% with pooled tirzepatide doses, versus 8.2% and 2.6% with placebo. About a quarter of the weight lost was lean mass in both groups.

Limitations & adverse findings

Both fat and lean mass declined. These results do not establish muscle preservation.

What might this mean? · interpretation

The proportion of weight loss attributed to lean mass differs from the percentage of starting lean mass lost.

What might this mean, and what would change the interpretation?

DXA lean mass is not a direct measure of contractile muscle or strength. This was a 160-person substudy, not the full randomized population.

What would clarify this: Muscle function, regional muscle measures and longer-term follow-up.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

The source links a published correction (DOI 10.1111/dom.70050). Correction text was unavailable in this review; values here are from the current abstract.

SURMOUNT-1 body-composition substudy
Human · BimagrumabCan fat mass fall while lean mass increases?
Human

Can fat mass fall while lean mass increases?

48 weeks; IV bimagrumab every 4 weeks, with diet and exercise counseling in both groups.

Demonstrated findings

At 48 weeks, fat mass changed by −20.5% with bimagrumab versus −0.5% with placebo; lean mass changed by +3.6% versus −0.8%.

Limitations & adverse findings

The report analyzed treatment completers, which can affect interpretation. The abstract provides limited adverse-event detail.

What might this mean? · interpretation

The result supports studying activin-receptor blockade for body composition.

What might this mean, and what would change the interpretation?

75 adults with type 2 diabetes and overweight or obesity were randomized; 58 completed. This was not a GLP combination trial and does not establish preserved strength.

What would clarify this: Controlled combination trials measuring both muscle composition and function.

Findings reviewed · abstract

Checked Sep 15, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.

Heymsfield et al., bimagrumab phase 2 trial
Human · IbutamorenDoes increased lean mass also mean better strength?
Human

Does increased lean mass also mean better strength?

65 adults aged 60–81; randomized, placebo-controlled study.

Demonstrated findings

A randomized trial in older adults increased GH, IGF-1 and fat-free mass, without improving strength or physical function.

What might this mean? · interpretation

Hormonal and body-composition changes can occur without a demonstrated functional improvement.

What might this mean, and what would change the interpretation?

Older adults differ from young trained athletes; appetite, edema and glucose-related effects matter to interpretation.

What would clarify this: Trials measuring muscle function and composition in the population of interest.

Oral ghrelin mimetic in healthy older adults
Animal · MOTS-cCan muscle preservation occur without preventing overall weight loss?
Animal

Can muscle preservation occur without preventing overall weight loss?

Demonstrated findings

In a C26 cancer-cachexia mouse model, MOTS-c preserved quadriceps mass relative to vehicle, without preventing overall body-weight loss.

What might this mean? · interpretation

Muscle-specific effects may differ from changes on a body-weight scale.

What might this mean, and what would change the interpretation?

A cancer-cachexia mouse model does not predict muscle gain in healthy people or effects during GLP-1 treatment.

What would clarify this: Replication across models and controlled human measurements of muscle mass and function.

Mechanism to possible human relevance
Working explanation
The mouse result suggests muscle and whole-body weight may respond differently in a disease model.
Possible human implication, hypothesis
Preserving muscle in other wasting settings is worth testing; preservation during GLP treatment remains a separate hypothesis.
Evidence that would support it
Replication with function measures and controlled trials in the relevant human population.
Evidence that would challenge it
No preservation outside the original model, or mass changes without meaningful functional benefit.
MOTS-c in cancer-associated muscle wasting

What would move this question forward?

Which interventions preserve muscle size and strength during GLP-associated weight loss, and in whom?

  • Change in fat mass
  • Change in lean mass and how it was measured
  • Muscle size, strength and physical function
  • Population, nutrition, activity and treatment duration

For emerging mechanisms, replication and the absence of the predicted effect both matter. Human implications remain hypotheses until the relevant outcomes are tested.

Community experiences & questions
Different experiences with mitochondrial compounds

Comments describe subtle energy changes with MOTS-c or SLU-PP-332 and no perceived benefit from SS-31 for one commenter.

Mixed compounds and subjective impressions; timing, other interventions and product identity are not controlled. This is a discussion sample, not a community consensus.

Self-selected accounts can reveal questions and experiences; they do not establish a response rate or verified product identity.

Keep exploring

Does more lean mass mean more strength?How do GLPs compare beyond the weight-loss headline?What changes with testosterone treatment?